| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | UBE2M |
| Uniprot No | P61081 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-183aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSHMIKLFS LKQQKKEEES AGGTKGSSKK ASAAQLRIQK DINELNLPKT CDISFSDPDD LLNFKLVICP DEGFYKSGKF VFSFKVGQGY PHDPPKVKCE TMVYHPNIDL EGNVCLNILR EDWKPVLTIN SIIYGLQYLF LEPNPEDPLN KEAAEVLQNN RRLFEQNVQR SMRGGYIGST YFERCLK |
| 预测分子量 | 24 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于UBE2M重组蛋白的3篇模拟参考文献及其摘要概括(基于公开领域知识整合，非真实文献)：
---
1. **文献名称**: *Structural Insights into UBE2M-mediated NEDD8 Conjugation*
**作者**: Zhang, Y., et al.
**摘要**: 该研究解析了UBE2M与NEDD8蛋白复合物的晶体结构，揭示了UBE2M催化NEDD8(类泛素蛋白)转移至Cullin蛋白的关键作用。通过重组UBE2M蛋白的体外实验，阐明了其活性位点及与E3连接酶的协同机制，为靶向泛素化通路的药物设计提供结构基础。
2. **文献名称**: *UBE2M is Essential for Cullin-RING Ligase Activation and Cell Cycle Progression*
**作者**: Harper, J.W., & Schulman, B.A.
**摘要**: 研究利用重组UBE2M蛋白和敲除模型，证明UBE2M通过介导Cullin蛋白的NEDD8修饰，调控Cullin-RING E3连接酶的活性。实验显示UBE2M缺失导致细胞周期停滞，强调其在维持蛋白稳态和细胞增殖中的必要性。
3. **文献名称**: *Recombinant UBE2M Expression and Enzymatic Characterization in Cancer Models*
**作者**: Li, H., et al.
**摘要**: 该研究在大肠杆菌中高效表达并纯化重组UBE2M蛋白，分析了其酶动力学参数及在肿瘤细胞中的异常表达。实验表明UBE2M通过促进致癌蛋白的稳定性驱动肿瘤生长，提示其作为癌症治疗靶点的潜力。
---
**注**：以上文献为示例性内容，实际引用时需通过学术数据库(如PubMed、Web of Science)检索真实文献并核实信息。
UBE2M, also known as Ubc12. is a member of the ubiquitin-conjugating enzyme E2 family, playing a critical role in the neddylation pathway—a post-translational modification analogous to ubiquitination. It specifically transfers NEDD8 (neural precursor cell-expressed developmentally downregulated protein 8), a ubiquitin-like protein, to cullin subunits of cullin-RING ligases (CRLs). This modification activates CRLs, the largest class of E3 ubiquitin ligases, which regulate ubiquitination and proteasomal degradation of substrates involved in cell cycle progression, DNA repair, and signal transduction. Dysregulation of UBE2M-mediated neddylation is implicated in cancers, neurodegenerative disorders, and immune dysfunctions.
Recombinant UBE2M protein is engineered via heterologous expression systems (e.g., *E. coli* or mammalian cells*) for biochemical and functional studies. Its production enables precise investigation of neddylation mechanisms, CRL activation kinetics, and interactions with E1 (NAE1-UBA3) or E3 enzymes. Researchers utilize recombinant UBE2M to screen inhibitors targeting the neddylation pathway, a therapeutic strategy for cancers with CRL hyperactivation. Structural studies, facilitated by recombinant protein crystallization, reveal binding interfaces for drug design.
Key features include high purity (>95%), preserved enzymatic activity, and tags (e.g., His-tag) for affinity purification. Mutant variants (e.g., catalytic cysteine mutants) serve as controls to dissect enzymatic steps. As a research tool, recombinant UBE2M advances understanding of protein homeostasis, offering insights into diseases linked to neddylation defects and guiding development of small-molecule modulators. Its applications span cancer biology, neurodegeneration models, and high-throughput drug discovery platforms.
×
